One-Hour Delivery Service Holds Potential to Disrupt Industry
Source: Anthony Varrell for Streetwise Reports  (3/4/19)
Kelly Abbott, CEO of ParcelPal Technology, sits down with Anthony Varrell of StoneBridge Partners to discuss his company's disruptive technology and expansion plans into the United States. More >

Medical Use of Nitric Oxide Expands as Costs Come Down
Source: Streetwise Reports  (9/19/18)
Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system. More >

Firm with U.S. Uranium Mines Poised to Benefit from Anticipated Changes in the Market
Source: Streetwise Reports  (7/26/18)
The U.S. Department of Commerce investigation into whether uranium imports threaten national security could lead to the imposition of tariffs that would benefit firms with American mines such as Azarga Uranium. Streetwise Reports spoke with Azarga's chairman Glenn Catchpole and CEO Blake Steele about the state of the uranium market and the company's recent merger with URZ Energy. More >

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way
Source: Streetwise Reports  (5/16/18)
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. More >

Biotech Advances Treatments for Liver Disease, Pain, Mental Illness
Source: Streetwise Reports  (3/22/18)
With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018.
More >

Cobalt Pure-Play Hitched to Electric Vehicle Boom
Source: Streetwise Reports  (11/21/17)
Forecasts of an electric vehicle boom are behind skyrocketing demand for cobalt, a major component in batteries. In this interview with The Energy Report, Anthony Milewski, CEO of Cobalt 27 Capital Corp., discusses the company's unique position as a two-pronged pure-play on cobalt. More >

Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End
Source: Streetwise Reports  (10/4/17)
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi.
More >

Peru Acquisition Could Increase Silver Miner's Production by 75%
Source: Streetwise Reports  (8/2/17)
With the closing of the Coricancha acquisition, Great Panther expands its operations into Peru. In this interview with The Gold Report, CEO Robert Archer discusses the plans for operating Coricancha, the company's growth strategy and his decision to step down as CEO. More >

Explorer on Target to Issue Upgraded Resource by Early Fall
Source: Streetwise Reports  (7/20/17)
Southern Silver Exploration's core drill program at Cerro Las Minitas in Durango, Mexico, is coming to an end and the company sees the potential for a substantial resource upgrade, say Robert Macdonald, Southern Silver's VP for Exploration, and Jay Oness, VP for Investor Relations. In this interview with Streetwise Reports, they also discuss the recently acquired additional claims, the Oro project in New Mexico and the JV with Electrum. More >

Aggressive Drill Program Could Focus Attention on Wyoming Gold Project
Source: The Gold Report  (6/29/17)
Wyoming currently does not have an active gold mine, but GFG Resources is out to change that with a drill program that is both focused on defining ounces for a maiden resource and looking for new gold discoveries, says Brian Skanderbeg, GFG's CEO. More >

The Discoveries Keep on Coming for Quebec Gold Explorer
Source: The Gold Report  (6/27/17)
Balmoral Resources' drilling keeps discovering new zones of gold mineralization at the Martiniere property in Quebec, says CEO Darin Wagner, and he expects the trend to continue with the summer drill program just getting underway. More >

Feasibility Study Offers Optionality to Maximize Cash Flow
Source: The Gold Report  (6/15/17)
Peter Breese, CEO of Asanko Gold, discusses the recently released definitive feasibility study for the Asanko Gold Mine in Ghana, and the two-stage organic growth plan. More >

Will Relief Canyon Be the Next Mine in Nevada?
Source: The Gold Report  (6/8/17)
Pershing Gold just released its prefeasibility study on the Relief Canyon Mine, and in this interview with The Gold Report, Pershing CEO Stephen Alfers discusses the economics of the Nevada project and his company's plans to advance it. More >

Inovio Moves Forward on Brain Cancer and Cancers Caused by HPV; Zika and Ebola Vaccines Also Advance
Source: The Life Sciences Report  (5/17/17)
Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses. More >

3D Signatures' Platform Taps into the Power of the Genome
Source: The Life Sciences Report  (5/10/17)
How fast is my cancer progressing? Does this treatment present my best option for a cure? These two big questions, which determine outcomes for patients with serious diseases such as Hodgkin's lymphoma, prostate cancer and Alzheimer's disease, are addressed by the platform technology in development by 3D Signatures Inc. In this interview with The Life Sciences Report, 3DS's new Chief Scientific Officer, Dr. Kevin Little, describes the TeloView platform, its utility in the marketplace and what makes it a compelling investment. More >

The ProMIS of an Alzheimer's Cure
Source: The Life Sciences Report  (5/3/17)
With the impacts of Alzheimer's disease on patients, doctors and the health care industry expected to burgeon over the next decade, ProMIS Neurosciences has developed a preclinical program that targets the root cause of the disease, and also offers the potential to get in on an investment with a double bottom line, says Elliot Goldstein, CEO of ProMIS, in this interview with The Life Sciences Report.
More >

Integra Gold Is Entering Unicorn Territory
Source: The Gold Report  (4/6/17)
Companies tend to excel at exploration or development, but Integra Gold seems to do both well simultaneously. In this interview with The Gold Report, Integra CEO Stephen de Jong explains Integra's dual track, discusses the company's latest PEA and resource update, and enumerates Integra's path to production. More >

Many Paths to Success with DURECT's Pipeline
Source: Dr. James Brown for The Life Sciences Report  (3/29/17)
DURECT has a pipeline of drugs for a wide range of indications, from NASH to psoriasis to postoperative pain. In this interview with The Life Sciences Report, Dr. James Brown, DURECT's President and CEO, discusses the potentially groundbreaking epigenetic regulator DUR-928, POSIMIR's late-stage testing for postoperative pain and an abuse-deterrent oral technology. More >

Fission Uranium's Exploratory Drilling Hits Success Right Out of the Gate
Source: Ross McElroy for The Energy Report  (3/23/17)
With uranium up 40% off last year's lows, a glimmer of optimism is returning to the uranium market, says Fission Uranium's President, COO and Chief Geologist Ross McElroy. In this interview with The Energy Report, McElroy discusses the company's latest drill results, its winter drilling plans and why he believes Fission could be on the cusp of a major discovery. More >

Great Panther Is on the Prowl for Acquisitions
Source: Bob Archer for The Gold Report  (3/14/17)
Great Panther Silver's modus operandi is to buy a past-producing mine, get it up and running as quickly as possible, and use the cash flow to fund more acquisitions, says CEO Bob Archer in this interview with The Gold Report. Having succeeded in Mexico with Guanajuato and Topia, the company is now taking on Coricancha in Peru. More >

MAG Silver's World-Class Property Just Keeps Getting Better
Source: The Gold Report  (3/7/17)
MAG Silver appears to have the Midas touch: Everything it drills turns up silver—with a gold byproduct and lots of zinc, lead and copper thrown in for good measure. MAG's first drill hole discovered the Juanicipio vein and hole #16 discovered the Valdecañas vein, both world-class deposits. In this interview with The Gold Report, MAG CEO George Paspalas discusses the company's JV in the Fresnillo Trend, the latest off-the-chart deep discoveries and where MAG goes from here. More >

RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology
Source: The Life Sciences Report  (2/22/17)
RXi Pharmaceuticals' proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. More >

Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs
Source: The Life Sciences Report  (8/17/16)
Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. More >

Seabridge Is Turning Cash into Gold
Source: The Gold Report  (8/4/16)
Seabridge Gold hosts one of the world's largest gold resources, offering shareholders exceptional leverage to a rising gold price. Chairman and CEO Rudi Fronk explains his company's value-enhancing strategy of obtaining resources at low cost and spinning them into gold. More >

Potential of High-Grade Gold Deposits Draws Adamera to Washington
Source: The Gold Report  (6/23/16)
Washington State has seen substantial historical gold mining dating back to the 1890s, but that doesn't mean there still isn't gold to be mined. Mark Kolebaba, CEO of Adamera Minerals, extols the advantages of exploring in Washington and explains why it offers low-cost opportunities. More >